AFP and liver cancer: The efficacy of TACE varies concerning tumor response and survival (8,13, , , –17) and may be associated with several factors such as tumor size, Child Pugh class, Barcelona clinic liver cancer (BCLC) stage, tumoral enhancement or peritumoral portal lipiodol enhancement (PPLE) during TACE, serum C-reactive protein (CRP), serum albumin, and alpha-fetoprotein (AFP) levels (18, , , , , , –25).